TNFSF9
Tumor necrosis factor ligand superfamily member 9
Also known as: 4-1BB-L, 4-1BBL, CD137L, TNFL9_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- P41273
- Gene
- TNFSF9
- Ensembl
- ENSG00000125657
- Chromosome
- 19
- Canonical length
- 254 aa
- Protein class
- Plasma proteins, Predicted intracellular proteins
- Subcellular location
- Golgi apparatus
- Quaternary structure
- Homotrimer
OverviewNCBI Gene
The protein encoded by this gene is a cytokine that belongs to the tumor necrosis factor (TNF) ligand family. This transmembrane cytokine is a bidirectional signal transducer that acts as a ligand for TNFRSF9/4-1BB, which is a costimulatory receptor molecule in T lymphocytes. This cytokine and its receptor are involved in the antigen presentation process and in the generation of cytotoxic T cells. The receptor TNFRSF9/4-1BB is absent from resting T lymphocytes but rapidly expressed upon antigenic stimulation. The ligand encoded by this gene, TNFSF9/4-1BBL, has been shown to reactivate anergic T lymphocytes in addition to promoting T lymphocyte proliferation. This cytokine has also been shown to be required for the optimal CD8 responses in CD8 T cells. This cytokine is expressed in carcinoma cell lines, and is thought to be involved in T cell-tumor cell interaction.[provided by RefSeq, Oct 2008]
Canonical amino-acid sequenceUniProt
254 residues, UniProt reviewed canonical sequence.
>P41273|TNFSF9
1 MEYASDASLD PEAPWPPAPR ARACRVLPWA LVAGLLLLLL LAAACAVFLA CPWAVSGARA
61 SPGSAASPRL REGPELSPDD PAGLLDLRQG MFAQLVAQNV LLIDGPLSWY SDPGLAGVSL
121 TGGLSYKEDT KELVVAKAGV YYVFFQLELR RVVAGEGSGS VSLALHLQPL RSAAGAAALA
181 LTVDLPPASS EARNSAFGFQ GRLLHLSAGQ RLGVHLHTEA RARHAWQLTQ GATVLGLFRV
241 TPEIPAGLPS PRSELocalizationUniProt · AlphaFold · HPA
Whether an antibody against TNFSF9 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Cell surface
- Secreted
- No
- Transmembrane segments
- 1
- Mean surface accessibility (rSASA)
- 0.44
- Highest tissue expression
- 9.6 nTPM
Expression across tissuesHPA
Tissue
- esophagus: 9.6 nTPM
- vagina: 9.1 nTPM
- cervix: 5 nTPM
- lung: 4.7 nTPM
- cerebral cortex: 3.6 nTPM
- bone marrow: 3.5 nTPM
Single-cell type
- epididymal basal cells: 70 nCPM
- pdcs: 61 nCPM
- alveolar cells type 2: 38 nCPM
- cdc: 37 nCPM
- b-cells: 35 nCPM
- t-cells: 31 nCPM
Immune cell
- memory CD8 T-cell: 0.8 nTPM
- memory B-cell: 0.4 nTPM
- plasmacytoid DC: 0.2 nTPM
- gdT-cell: 0.1 nTPM
- naive CD8 T-cell: 0.1 nTPM
- basophil: 0 nTPM
Brain region
- cerebral cortex: 13 nTPM
- white matter: 11 nTPM
- cerebellum: 5.7 nTPM
- medulla oblongata: 5.7 nTPM
- pons: 5.4 nTPM
- amygdala: 5.3 nTPM
ReferencesPubMed · IEDB
Publications for TNFSF9 from three distinct lines of evidence, kept separate because they answer different questions: whether antibodies are directed at the protein, whether a B-cell epitope has been mapped on it, and whether a T-cell epitope has. Each is labelled with its source.
Reference: AutoantibodyPubMed
1 publication
Sources: PubMed — antigen-level antibody evidence from a custom retrieval. Records matching a controlled set of autoantibody terms (the MeSH descriptors Autoantibodies and Autoantigens, with title and abstract term variants) were obtained through NCBI E-utilities, and their titles and abstracts parsed for constructions that direct an antibody at a named protein rather than for co-occurrence. Captured names were resolved against UniProt nomenclature and each antigen adjudicated individually against the source text. Bibliographic records from PubMed and MeSH, U.S. National Library of Medicine; citation metrics from NIH iCite (Hutchins et al., PLoS Biology 2016). Titles link to PubMed; abstracts are not reproduced here. The NLM does not endorse this analysis.
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.12
- gnomAD pLI
- 0.32
- gnomAD missense Z
- -0.48
- DepMap mean gene effect
- -0.06
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- cell-cell signaling
- immune response
- positive regulation of activated T cell proliferation
- positive regulation of cytotoxic T cell differentiation
- regulation of apoptotic process
- regulation of T cell proliferation
Molecular functions
- cytokine activity
- signaling receptor binding
- tumor necrosis factor receptor binding
- tumor necrosis factor receptor superfamily binding
Cellular components
Protein domainsUniProt · Pfam · InterPro
- Tumour necrosis factor domain
- Tumour necrosis factor-like domain superfamily
- Tumour necrosis factor, conserved site
- TNF(Tumour Necrosis Factor) family
- Tumor necrosis factor ligand superfamily member 9
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads TNFSF9 as an antibody target. Whether an autoantibody or antibody against TNFSF9 could matter depends on whether native TNFSF9 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
TNFSF9 is annotated at the cell surface, where native TNFSF9 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.
Annotation status
The present source text does not explicitly label TNFSF9 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...